Check a new therapy for osteoporosis-related hip bone loss
Part of Bones, joints & muscles, Hormones & metabolism, Injuries & trauma clinical trials.
This trial studies AGN1 LOEP, a treatment being tested to improve bone strength in people with osteoporosis-related bone loss in the hip. If you qualify, you would be followed over time with clinic visits and testing to see how the treatment affects your bone health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a postmenopausal woman and have been past your last period for at least 1 year
- Your hip bone density test shows osteoporosis (femoral neck T-score of -2.5 or lower)
- You have at least one hip with no previous surgery or hip fracture
- You can take part in all study visits and follow-up testing, and you can sign written consent
- You are generally healthy enough for the study (ASA class I or II)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at how well AGN1 LOEP—a bone-strengthening treatment—worked for people who received it in their hip bone. Researchers want to understand real-world results to help future patients.
This trial tests AGN1 LOEP (a medicine/device placed at the hip surgery site) to help prevent another hip fracture after you’ve had a low-energy hip fracture. You must be eligible for hip repair surgery and be at higher risk for another fracture, with no key exclusions like active cancer or serious kidney disease.
This study is a follow-up for people who completed a previous precision medicine trial for osteoporosis. It will monitor your bone health to see how well the treatment is working over time.
This trial uses scans like X-rays, CT, or MRI to study how bones and joints age. It aims to understand aging-related problems and may help develop better ways to detect or treat them.
This study compares two treatments for osteoporosis in postmenopausal women: a sequence of romosozumab followed by denosumab versus zoledronic acid alone. The goal is to see which approach better improves bone density in the hip. Participants will receive either the combination or the single drug for a period, and their progress will be monitored.
This study looks for new markers and treatment targets for osteoporosis by comparing bone tissue from women with a broken hip (due to weak bones) and women getting a hip replacement for arthritis. You may be eligible if you are postmenopausal and have one of these hip conditions.
Hear when a new Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.